A musty moldy odor linked to a trace chemical sends yet another Tylenol recall to be announced by Johnson & Johnson.
The McNeil Consumer Healthcare unit is recalling one product lot of Tylenol Extra Strength Caplets that were distributed in the U.S. The recall includes about 60,912 bottles that were made in February 2009. Each of those bottles contains 225 caplets.
There were a small number of reports about these recalled pills and an odor they were giving off. The odor has been linked in the past Johnson & Johnson recalls to the presence of trace amounts of 2,4,6-tribromoanisole, according to Atlanta Journal-Constitution. TBA is a byproduct of a chemical preservative (sometimes used on shipping pallets).
TBA has been associated with non-serious and temporary gastrointestinal symptoms. The New Brunswick, N.J. based Johnson & Johnson company since September 2009, has had about two dozen recalls of nonprescription and prescription medicines, contact lenses, diabetes test strips, and replacement hips. Included in the many recalls were tens of millions of bottles of children’s and adult Tylenol and Motrin.
The high number of recalls has obviously affected Johnson & Johnson revenue and stock price. Johnson & Johnson says that it has inspected its plants worldwide and invested millions of dollars in order to improve the quality of its 
manufacturing and satisfy federal regulators. After so many recalls Johnson & Johnson is under strict scrutiny.
This specific Tylenol Extra Strength product recall lot number is ABA619 300450444271. If you have this recalled product, please stop using it and contact McNeil at www.tylenol.com or by calling 1-888-222-6036 for instructions on receiving a refund or product coupon.
Contact Us
If you have further legal questions please feel free to contact us today for a free consultation to learn more about your legal rights and options.
Other Dangerous Drugs News
Research suggests Dupixent (dupilumab) may be linked to an increased risk of cutaneous T-cell lymphoma (CTCL). Learn what studies show, how CTCL may be misdiagnosed as eczema, and the legal options for patients diagnosed with lymphoma after taking Dupixent.
Childers, Schlueter & Smith has filed the first Dupixent lawsuit in Georgia, alleging a link between the eczema drug and cutaneous T-cell lymphoma (CTCL). The complaint highlights questions about risk disclosure.
A recent FDA-approved label change now warns of brain meningioma risks linked to Depo-Provera. This update explains what changed, why lawsuits are being filed, and what the warning may mean for women diagnosed with brain tumors.
While Suboxone helps fight opioid addiction, it’s now at the center of a growing legal battle over severe, preventable dental harm not disclosed to patients for years.
Women across the U.S. are filing lawsuits against Pfizer after a major study linked long-term use of Depo-Provera to a fivefold increase in the risk of developing brain tumors known as meningiomas.
Women diagnosed with meningiomas after using Depo-Provera may be eligible for financial compensation, as lawsuits claim Pfizer failed to warn about the potential risk of brain tumors.
